Overview

Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of radiotherapy combined with GDP (gemcitabine, cisplatin, dexamethasone) chemotherapy in stage I/II extranodal natural killer/T-cell lymphoma patients with unfavorable prognostic factors.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Treatments:
BB 1101
Cisplatin
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Gemcitabine